Mycophenolate Mofetil in Low Doses Stabilizes and Improves Antineutrophil Cytoplasmic Antibody-associated Vasculitis and Lupus Nephritis

Hypomethylation of long interspersed nucleotide element‐1 in peripheral mononuclear cells of juvenile systemic lupus erythematosus patients in China

“…Successes in biomarker discovery over the past 5 years will likely facilitate the management of JSLE in the upcoming years. Three novel biomarkers currently under study are cell‐bound biomarkers, genomic biomarkers in the blood, and urinary biomarkers . In a study by Lin et al .…”

“…Three novel biomarkers currently under study are cell-bound biomarkers, genomic biomarkers in the blood, and urinary biomarkers. [30][31][32][33][34][35][36] In a study by Lin et al in 2011, hypomethylated IL-10 and IL-1R2 genes were found to be associated with disease activity of SLE, indicating that DNA hypomethylation may provide potential epigenetic markers for clinical prediction for SLE. 37 As confirmed by our research, the methylation levels of LINE-1 correlated well with disease activity and C3 levels.…”

Mycophenolate Mofetil vs Azathioprine for Remission Maintenance in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis

“…9,10 In AAV, small observational studies and randomized controlled trials reported successful remission induction [11][12][13] and remission maintenance with mycophenolate mofetil. [14][15][16] Whether mycophenolate mofetil is more effective than azathioprine for preventing relapses in AAV is…”

Treatment of ANCA-Associated Vasculitis: New Therapies and a Look at Old Entities

“…Small observational studies have suggested that MMF may be efficacious for maintenance of remission in patients with AAV. [87][88][89] The EUVAS study evaluated the use of MMF (2000 mg/day) compared to azathioprine (2 mg/kg/day) in a randomized controlled trial of 156 newly diagnosed patients who achieved remission after induction with CYC and glucocorticoids. 86 Patients were followed for a median of 39 months with the primary endpoint of relapse-free survival.…”